TB-500 (Thymosin Beta-4 Fragment) — Research Overview

TB-500 is a synthetic peptide modeled after a region of thymosin beta-4 (Tβ4), widely discussed in research settings for its potential roles in tissue repair, angiogenesis, and inflammation modulation. This page is for research use context only and is not medical advice.

Research Use Disclaimer: This content is provided for educational and research discussion only. TB-500 / thymosin beta peptides are not approved by the FDA for bodybuilding, injury treatment, or cosmetic uses. Do not use this information to diagnose, treat, cure, or prevent any disease.

Description

Thymosin beta-4 is a naturally occurring 43–amino acid peptide found in many tissues. It binds G-actin and is involved in cell migration and wound repair biology. “TB-500” is commonly marketed as a thymosin beta-4 fragment (varies by vendor), and research discussions often extrapolate from the larger Tβ4 literature.

Potential Research Benefits

  • Soft tissue repair signals: cell migration, extracellular matrix remodeling (preclinical).
  • Angiogenesis support: vascular growth signaling in wound models.
  • Anti-inflammatory signaling: modulation of inflammatory pathways in certain injury contexts.
  • Cardiac repair research: studied in myocardial injury models.
  • Hair follicle biology: Tβ4 has been evaluated in hair growth/wound healing contexts.

Mechanism of Action (Research Discussion)

Mechanistic work on thymosin beta-4 suggests effects related to actin sequestration, enhanced cell migration, and altered expression of repair-associated genes. In some models it has been linked to angiogenic signaling and changes in inflammatory mediators. Note: data are largely preclinical and context-dependent, and fragment peptides may not replicate full-length Tβ4 biology.

Side Effects (Anecdotal / Research Context)

  • Injection site irritation (if injected in research settings).
  • Transient fatigue or headache (anecdotal reports).
  • Unknown long-term risks due to limited controlled human data for TB-500 products.

Contraindications (Precautionary)

  • Pregnancy or breastfeeding (insufficient safety data).
  • Active malignancy or history of cancer (angiogenesis/growth signaling is a theoretical concern).
  • Use with anticoagulants/bleeding disorders: consult a clinician (general injection/hematoma risk).

SubQ vs IM (If Used in Injectable Research)

In underground research practice, TB-500 is commonly administered subcutaneously (SubQ) for convenience, while intramuscular (IM) injection is sometimes chosen when targeting local tissue regions. There is no high-quality evidence demonstrating superior outcomes for SubQ vs IM in humans.

Reconstitution (Example)

TB-500 is typically supplied as a lyophilized powder. In research settings it is often reconstituted with bacteriostatic water using aseptic technique.

2 mg vial example

Add 1.0 mL bac water → concentration = 2 mg/mL.

  • 0.10 mL (10 IU on a U-100 insulin syringe) = 0.20 mg
  • 0.25 mL (25 IU) = 0.50 mg
  • 0.50 mL (50 IU) = 1.0 mg

5 mg vial example

Add 2.0 mL bac water → concentration = 2.5 mg/mL.

  • 0.10 mL (10 IU) = 0.25 mg
  • 0.20 mL (20 IU) = 0.50 mg
  • 0.40 mL (40 IU) = 1.0 mg

Research Dosing (Common Non-Clinical Patterns)

Common informal protocol discussed online: 2–5 mg twice weekly for 2–6 weeks (“loading”), then ~2 mg weekly (“maintenance”). These are not clinically validated regimens.

Stacking Suggestions (Research Discussion)

  • BPC-157: often discussed alongside TB-500 for soft tissue repair research narratives.
  • Collagen support (nutrition, vitamin C): commonly paired in injury-rehab discussions (not peptide-specific evidence).
  • GH/IGF axis peptides: sometimes stacked in performance circles; increases complexity and unknowns.

Research Sources (PubMed)

  1. Thymosin beta-4 and wound repair biology. Ann N Y Acad Sci. 2007. PMID: 17413026
  2. Thymosin beta-4 promotes cardiac repair after myocardial infarction (preclinical). Nature. 2004. PMID: 15526016
  3. Thymosin beta-4 and corneal wound healing / inflammation modulation. Invest Ophthalmol Vis Sci. 2001. PMID: 11431452
  4. Tβ4 / actin-binding and cell migration relevance. J Cell Biol. 1990. PMID: 2403999
  5. Thymosin beta-4 in angiogenesis / vascular biology context. FASEB J. 2003. PMID: 12626435
  6. Thymosin beta-4 and hair follicle / skin repair-related research context. J Invest Dermatol. 2012. PMID: 22277948

If you want, I can add a compact “quick-dose math” table for a specific vial size you stock (2 mg, 5 mg, or 10 mg) and your preferred reconstitution volume.

Scroll to Top